Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate
Benzinga Newsdesk 7 months ago
EarningsEarnings BeatsEarnings MissesNews
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.22) by 20.61 percent. This is a 10 percent decrease over losses of $(1.60) per share from
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.22) by 20.61 percent. This is a 10 percent decrease over losses of $(1.60) per share from the same period last year. The company reported quarterly sales of $438.000 thousand which missed the analyst consensus estimate of $5.875 million by 92.54 percent.